← Back to Search

Nutritional Supplement

Enriched Eggs for Diabetic Retinopathy

N/A
Recruiting
Led By Miyoung Suh, RD, PhD
Research Sponsored by University of Manitoba
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Individuals with a fasting plasma glucose of ≥7.0 mmol/L or glycated hemoglobin (A1C) of ≥6.5% (these values are based on the Canadian Diabetes Association and are predictors of the development of diabetic retinopathy)
Individuals taking oral hypoglycemic medications (sulfonylureas, meglitinides, biguanides, thiazolidinediones etc.)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 weeks
Awards & highlights

Study Summary

This trialaims to assess if eating two DHA & lutein enriched eggs a day can improve eye health in those with diabetes, without impacting body composition & cardiovascular risk.

Who is the study for?
This trial is for adults over 19 with Type 2 diabetes who have a fasting plasma glucose of ≥7.0 mmol/L or A1C of ≥6.5%, and are taking oral hypoglycemic medications. It's not for those with cognitive diseases, eye diseases other than diabetic retinopathy, severe diabetic retinopathy, insulin users, cancer or anemia patients, or pregnant women.Check my eligibility
What is being tested?
The study tests if eating two DHA and lutein enriched eggs daily improves retina health in Type 2 diabetics compared to regular eggs. This double-blinded trial will measure changes in blood lipids, carotenoids, body composition and cardiovascular risk factors after six weeks.See study design
What are the potential side effects?
Potential side effects may include changes to cholesterol levels due to egg consumption; however specific side effects related to the enriched eggs aren't detailed but could be similar to regular egg consumption.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My blood sugar or A1C levels indicate I might develop diabetic eye disease.
Select...
I am taking oral medication for diabetes.
Select...
I have been diagnosed with Type 2 diabetes.
Select...
I am over 19 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Retina Function

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Enriched Egg GroupExperimental Treatment1 Intervention
Participants will consume 2 medium sized docosahexaenoic acid and lutein enriched eggs daily (at least 5 days per week) for 6 weeks.
Group II: Regular Egg GroupPlacebo Group1 Intervention
Participants will consume 2 medium sized non-enriched eggs daily (at least 5 days per week) for 6 weeks.

Find a Location

Who is running the clinical trial?

University of ManitobaLead Sponsor
595 Previous Clinical Trials
199,421 Total Patients Enrolled
Egg Farmers of CanadaUNKNOWN
2 Previous Clinical Trials
210 Total Patients Enrolled
Miyoung Suh, RD, PhDPrincipal InvestigatorUniversity of Manitoba

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the enrollment period open for this experiment?

"Affirmative. Data hosted on clinicaltrials.gov shows that this trial is still open for recruitment, having been first posted on July 11th 2022 and most recently updated November 1st 2022. This study requires 60 participants from a single facility."

Answered by AI

How many people are taking part in the current clinical experiment?

"Affirmative, the information available on clinicaltrials.gov suggests that recruitment is open for this medical trial. It was first published on July 11th 2022 and recently edited on November 1st 2022. 60 participants are necessary to be enrolled from a single health facility."

Answered by AI
~7 spots leftby Sep 2024